Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

6.41
+0.08001.26%
Pre-market: 6.580.1700+2.65%08:28 EDT
Volume:2.21M
Turnover:14.18M
Market Cap:943.54M
PE:-10.94
High:6.50
Open:6.36
Low:6.29
Close:6.33
52wk High:6.52
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:1.50
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:7.57
PE(LYR):-12.09

Loading ...

Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO

Reuters
·
Apr 10

Aclaris CEO to join fireside chat at H.C. Wainwright skin disease conference

Reuters
·
Apr 08

Aclaris Therapeutics Price Target Maintained With a $8.00/Share by Wedbush

Dow Jones
·
Mar 31

Aclaris Therapeutics Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%

Reuters
·
Mar 27

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

GlobeNewswire
·
Mar 27

Aclaris Therapeutics to present Phase 2a ATI-2138 atopic dermatitis trial results at 2026 AAD meeting

Reuters
·
Mar 20

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 19

Aclaris Therapeutics completes enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis

Reuters
·
Mar 18

Aclaris Therapeutics Inc - Top Line Results From Phase 2 Trial Expected in Q4 2026

THOMSON REUTERS
·
Mar 18

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

GlobeNewswire
·
Mar 18

Aclaris Therapeutics Raises $20 Million in Equity Financing

TIPRANKS
·
Mar 12

Aclaris Therapeutics sells 5.7 million shares for USD 20 million

Reuters
·
Mar 12

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

GlobeNewswire
·
Mar 03

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 27

Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Feb 26

Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)

TIPRANKS
·
Feb 26

Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate

Benzinga Earnings
·
Feb 26

Aclaris Q4 loss narrows, but misses analysts' expectations

Reuters
·
Feb 26

BRIEF-Aclaris Therapeutics Q4 Net Income USD -19.795 Million Vs. IBES Estimate USD -17.6 Million

Reuters
·
Feb 26

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Feb 26